breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology
breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship
Tan AS, Nagler RH, Hornik RC, DeMichele A: Evolving information needs among colon, breast, and prostate cancer survivors: results from a longitudinal mixed- effects analysis. Cancer Epidemiol Biomarkers Prev 24: 1071-8, July 2015.
Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ: Association between self-report adherence measures and oestrogen supression among breast cancer survivors on aromatase inhibitors. European Journal of Cancer Epub ahead of print, July 10 2015.
Ou Y, Weinstein SP, Conant EF, Englander S, Da X, Gaonkar B, Hsieh MK, Rosen M, DeMichele A, Davatzikos C, Kontos D: Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy. Magnetic Resonance Medicine 73(6): 2343-56, Jun 2015.
Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ: Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with comorbid fatigue and insomnia? Breast Cancer Research 17: 89, June 2015.
Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D: Breast DCE-MRI kinetic heterogeneity tumor markers: Preliminary associates with neoadjuvant chemotherapy response. Translational Oncology 8(3): 154-62, June 2015.
Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R: Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. Breast Cancer Research 17: 72, May 2015.
Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ: Anti- HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2- positive breast cancer. Breast Cancer Research 17: 71, May 2015.
Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.: Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small cell lung cancer, non small cell lung cancer, head and neck squamous carcinoma and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncology(4), 395-405, Apr 16 2015.
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment. Clinical Cancer Research 21(5): 995-1001, March 2015.
White J, DeMichele A: Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care. American Society of Clinical Oncology Education Book 35: 17-23, 2015.
back to top
Last updated: 07/14/2016
The Trustees of the University of Pennsylvania